Related Experiment Videos

Psychoactive drugs in children

M V Johnston1

  • 1Johns Hopkins University School of Medicine, Baltimore, Maryland.

Insights

Routine monitoring of anticonvulsant drugs is likely unnecessary for most patients. High-risk groups, including those with metabolic disorders or neurodegenerative diseases, may still benefit from monitoring.

Area of Science:

  • Pharmacology and Therapeutics
  • Pediatric Medicine
  • Clinical Drug Monitoring

Background:

  • Anticonvulsant drug monitoring may not be universally required.
  • Specific patient populations may necessitate closer monitoring.
  • Pediatric sedation practices involve midazolam and analgesics.

Purpose of the Study:

  • To evaluate the necessity of routine anticonvulsant drug monitoring.
  • To review pharmacokinetic differences in children versus adults.
  • To assess the safety and efficacy of midazolam and analgesics for pediatric sedation.

Main Methods:

  • Literature review of studies on anticonvulsant drug monitoring.
  • Analysis of pharmacokinetic data comparing pediatric and adult populations.
  • Review of safety and kinetic data for midazolam and fentanyl in pediatric procedures.

Main Results:

  • Plasma carnitine reduction by anticonvulsants is noted, but clinical significance is unclear.
  • Midazolam and fentanyl are effective for pediatric procedural sedation, reducing anxiety and memory.
  • Methylphenidate for hyperactivity and risks of tricyclic antidepressants in children were also reviewed.

Conclusions:

  • Anticonvulsant drug monitoring is likely unnecessary for the general patient population.
  • High-risk groups, including those with metabolic disorders, neurodegenerative diseases, or prior drug reactions, may require monitoring.
  • Further research is needed to clarify the clinical significance of anticonvulsant-induced plasma carnitine reduction.

Related Concept Videos